Pre-existing diabetes mellitus is associated with a shorter PSA doubling time (PSADT) in prostate cancer patients who experience biochemical recurrence after radical prostatectomy (RP), according to researchers.
Jong Jin Oh, MD, of CHA Bundang Medical Center, CHA University, Seongnam, Korea, and colleagues analyzed data from 661 men who underwent RP for node-negative cancer and were followed for at least three years. Of the 661 men, 67 had diabetes mellitus and 594 did not.
Among the 60 patients who had biochemical recurrence of cancer, PSADT was calculable in 58 (96.7%): nine in the diabetes group and 49 in the non-diabetic group. The median PSADT was 9.24 months among the non-diabetics compared with 6.35 months in the diabetics, the investigators reported in International Urology and Nephrology. Multivariate analysis showed that diabetes was associated with a significant 2.7 times increased likelihood of a PSADT less than nine months compared with the absence of diabetes.
The researchers acknowledged that the relatively small number of diabetics was a study limitation, as was the study’s retrospective design.